Zobrazeno 1 - 10
of 605
pro vyhledávání: '"Jordi Bruix"'
Autor:
José Ríos, Víctor Sapena, Zoe Mariño, Jordi Bruix, Xavier Forns, Rosa Morros, María Reig, Ferran Torres, Caridad Pontes
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 3, Pp 389-401 (2024)
Abstract Background and Objectives Direct-acting antivirals (DAAs) offer a high rate of hepatitis C virus (HCV) eradication. However, concerns on the risk of cancer after HCV eradication remain. Our study aimed at quantifying the incidence of cancer
Externí odkaz:
https://doaj.org/article/34e92b905d0847f391b867ed2b47fb9f
Autor:
Antonietta Romano, Alessandra Brocca, Zoe Mariño, Sofía Pérez-del-Pulgar, Sabela Lens, Loreto Boix, María Reig, Jordi Bruix, Giulio Ceolotto, Valeria Calvino, Gianluca Zilio, Paula Piñero Romero, Ranka Vukotic, Valeria Guarneri, Pietro Andreone, Saverio Giuseppe Parisi, Francesco Paolo Russo, Salvatore Piano, Umberto Cillo, Paolo Angeli
Publikováno v:
Livers, Vol 4, Iss 2, Pp 275-286 (2024)
Background: The risk of hepatocarcinoma in HCV cirrhotic patient responders after treatment with DAAs decrease, but HCC still occurs. A correlation between specific miRNAs and the development of hepatocarcinoma have been highlighted. Aim: To investig
Externí odkaz:
https://doaj.org/article/29e4f2d1e6f24c26bfe60b825e287e70
Autor:
Miguel Angel Merlos Rodrigo, Hana Michalkova, Ana Maria Jimenez Jimenez, Frantisek Petrlak, Tomas Do, Ladislav Sivak, Yazan Haddad, Petra Kubickova, Vivian de los Rios, J. Ignacio Casal, Marina Serrano-Macia, Teresa C. Delgado, Loreto Boix, Jordi Bruix, Maria L. Martinez Chantar, Vojtech Adam, Zbynek Heger
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-18 (2024)
Abstract Background & aims Metallothionein-3 (hMT3) is a structurally unique member of the metallothioneins family of low-mass cysteine-rich proteins. hMT3 has poorly characterized functions, and its importance for hepatocellular carcinoma (HCC) cell
Externí odkaz:
https://doaj.org/article/7a0c75ad3012498a9f15fd7e736949c9
Autor:
Angeles Garcia-Criado, Jordi Rimola, Susana Seijo, Anna Darnell, Ernest Belmonte, Victor Sapena, Julián Moreno-Rojas, Valeria Pérez, Virginia Hernández-Gea, Carmen Ayuso, Maria Reig, Juan Carlos Garcia-Pagan, Jordi Bruix
Publikováno v:
Liver Cancer (2023)
Introduction The incidence of hepatocellular carcinoma (HCC) in Budd-Chiari syndrome (BCS) is unknown and there is no validated diagnostic work-up to define the liver nodules with arterial phase hyperenhancement (APHE) suggesting malignancy. This pro
Externí odkaz:
https://doaj.org/article/813f99e541e045f9a8aa41600680637f
Autor:
Loreto Boix, Víctor Sapena, Esther Samper, Álvaro Díaz-González, Neus Llarch, Gemma Iserte, Leonardo G. Da Fonseca, Marco Sanduzzi-Zamparelli, Alejandro Forner, Jordi Bruix, María Reig
Publikováno v:
Gastrointestinal Disorders, Vol 4, Iss 3, Pp 141-152 (2022)
Gastrointestinal adverse events (GIAEs) are common in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Diarrhea is a prevalent event responsible for treatment interruptions and dosage modifications. Our study evaluates th
Externí odkaz:
https://doaj.org/article/46e7da13fb49463898772c7a7112b9d5
Autor:
Stephen L. Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean-Frederic Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Eric Assenat, Andrew X. Zhu, Thomas Yau, Ho Yeong Lim, Jordi Bruix, Andreas Geier, Carmen Guillén-Ponce, Angelica Fasolo, Richard S. Finn, Jia Fan, Arndt Vogel, Shukui Qin, Markus Riester, Vasiliki Katsanou, Monica Chaudhari, Tomoyuki Kakizume, Yi Gu, Diana Graus Porta, Andrea Myers, Jean-Pierre Delord
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-19 (2022)
Abstract Background Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclin
Externí odkaz:
https://doaj.org/article/1a80d93b46254b83bfdf5d4c0de1a368
Autor:
Giuseppe Cabibbo, Maria Reig, Ciro Celsa, Ferran Torres, Salvatore Battaglia, Marco Enea, Giacomo Emanuele Maria Rizzo, Salvatore Petta, Vincenza Calvaruso, Vito Di Marco, Antonio Craxì, Amit G. Singal, Jordi Bruix, Calogero Cammà
Publikováno v:
Liver Cancer, Pp 1-10 (2021)
Introduction: Atezolizumab (ATEZO) plus bevacizumab (BEVA) represents the new standard of care for the treatment of advanced hepatocellular carcinoma (HCC). However, the choice of the second-line treatment after the failure of immunotherapy-based fir
Externí odkaz:
https://doaj.org/article/49f9c3951aad466793506f22ced773ef
Autor:
Manon Allaire, Jordi Bruix, Marko Korenjak, Sarah Manes, Zorana Maravic, Helen Reeves, Riad Salem, Bruno Sangro, Morris Sherman
Publikováno v:
JHEP Reports, Vol 4, Iss 12, Pp 100578- (2022)
Summary: Hepatocellular carcinoma (HCC) is a major public health problem worldwide for which the incidence and mortality are similar, pointing to the lack of effective treatment options. Knowing the different issues involved in the management of HCC,
Externí odkaz:
https://doaj.org/article/fe3debb260174a40998a6a79d188b5cc
Autor:
Sergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, Anna Darnell, Alejandro Forner, Ernest Belmonte, Marco Sanduzzi-Zamparelli, Jordi Rimola, Alexandre Soler, Neus Llarch, Gemma Iserte, Ezequiel Mauro, Carmen Ayuso, Jose Rios, Jordi Bruix, Ramon Vilana, María Reig
Publikováno v:
Cancers, Vol 15, Iss 13, p 3269 (2023)
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients’ outcomes after recurrence. The present study evaluates the impact of patient
Externí odkaz:
https://doaj.org/article/b7fc947808234c3ca012bbb28c8f01b2
Autor:
Pablo Fernández-Tussy, Rubén Rodríguez-Agudo, David Fernández-Ramos, Lucía Barbier-Torres, Imanol Zubiete-Franco, Sergio López de Davalillo, Elisa Herraez, Naroa Goikoetxea-Usandizaga, Sofia Lachiondo-Ortega, Jorge Simón, Fernando Lopitz-Otsoa, Virginia Gutiérrez-de Juan, Misti V. McCain, Maria J. Perugorria, Jon Mabe, Nicolás Navasa, Cecilia M. P. Rodrigues, Isabel Fabregat, Loreto Boix, Victor Sapena, Juan Anguita, Shelly C. Lu, José M. Mato, Jesus M. Banales, Erica Villa, Helen L. Reeves, Jordi Bruix, Maria Reig, Jose J. G. Marin, Teresa C. Delgado, María L. Martínez-Chantar
Publikováno v:
Cell Death and Disease, Vol 12, Iss 6, Pp 1-16 (2021)
Abstract Dysregulation of miRNAs is a hallmark of cancer, modulating oncogenes, tumor suppressors, and drug responsiveness. The multi-kinase inhibitor sorafenib is one of the first-line drugs for advanced hepatocellular carcinoma (HCC), although the
Externí odkaz:
https://doaj.org/article/fb7ef154614446039d3b36ccb14472c8